69 187

Cited 12 times in

Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities

Jung, HJ; Chen, Z; Wang, M; Fayad, L; Romaguera, J; Kwak, LW; McCarty, N
Blood, 119(11):2568-2578, 2012
Journal Title
Although bortezomib is clinically approved for the treatment of mantle cell lymphoma (MCL), only limited effects of this treatment have been demonstrated. To improve survival for bortezomib-resistant patients, it is necessary to develop new therapeutic strategies. In the present study, we used biochemical and molecular methodologies to demonstrate that tissue transglutaminase (TG) activates downstream NF-κB signaling pathways. The signaling axis from TG to NF-κB could be a new therapeutic target to overcome bortezomib resistance in MCL. TG2 is a calcium-dependent protein cross-linking enzyme reported to be overexpressed in various cancer cells. We found that MCL cells expressed elevated levels of TG2 and that the modification of TG2 activities altered NF-κB expression and downstream signaling in MCL cells. When TG2 signaling was inhibited by calcium blockers, the combination of a calcium blocker (perillyl alcohol) with bortezomib suppressed NF-κB expression and improved the cytotoxicity of bortezomib in MCL cells. Our study is the first to show the expression of TG2 and the contribution of TG2 to NF-κB signaling in MCL. TG2 inhibition may be used as an alternative target anti-MCL therapy, and calcium blockers may be combined with bortezomib to overcome the bortezomib resistance in MCL.
MeSH terms
AnimalsAntineoplastic Agents/*pharmacologyApoptosisBlotting, WesternBoronic Acids/*adverse effectsCalcium/*metabolismCell ProliferationDrug Resistance, Neoplasm/*drug effectsDrug SynergismFlow CytometryFluorescent Antibody TechniqueGTP-Binding Proteins/*metabolismHumansImmunoenzyme TechniquesLymphoma, Mantle-Cell/*drug therapy/metabolism/pathologyMiceMice, Inbred NODMice, SCIDMonoterpenes/*pharmacologyNF-kappa B/genetics/*metabolismPerilla/chemistryPyrazines/*adverse effectsTransglutaminases/*metabolismTumor Cells, CulturedXenograft Model Antitumor Assays
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pediatrics & Adolescent Medicine
AJOU Authors
정, 현주
Full Text Link
Files in This Item:
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.